Drug Trial Radar · NCT07242781
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
22
Actual
Start
Dec 15, 2025
Primary completion
Apr 9, 2026
Study completion Apr 21, 2026
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of Itraconazole and Rifampin on the drug levels of AR-LDD (BMS-986365) in healthy adult male participants.
Conditions
- Healthy Volunteers
Interventions
BMS-986365Drug
Specified dose on specified days
ItraconazoleDrug
Specified dose on specified days
RifampinDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Maximum Observed Plasma Concentration (Cmax) of BMS-986365Time frame: Up to approximately Day 32
- Part A: Cmax of BMS-986365 Without ItraconazoleTime frame: Up to approximately Day 32
- Part A: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) of BMS-986365 With ItraconazoleTime frame: Up to approximately Day 32
- Part A: AUC(0-T) of BMS-986365 Without ItraconazoleTime frame: Up to approximately Day 32
- Part A: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-986365Time frame: Up to approximately Day 32
- Part A: AUC(INF) of BMS-986365 Without ItraconazoleTime frame: Up to approximately Day 32
- Part B: Cmax of BMS-986365 With RifampinTime frame: Up to approximately Day 37
- Part B: Cmax of BMS-986365 Without RifampinTime frame: Up to approximately Day 37
- Part B: AUC(INF) of BMS-986365 With RifampinTime frame: Up to approximately Day 37
- Part B: AUC(INF) of BMS-986365 Without RifampinTime frame: Up to approximately Day 37
- Part B: AUC(0-T) of BMS-986365 With RifampinTime frame: Up to approximately Day 37
- Part B: AUC(0-T) of BMS-986365 Without RifampinTime frame: Up to approximately Day 37
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Local Institution - 0001
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.